Numerous clinical trials are always active (ie, open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. The buttons below depict the general research categories being investigated in ECOG-ACRIN clinical trials. To access information within a particular category, click on the relevant button. Upon clicking, the color of the button will change from grey to red, and a table will appear on screen. The table will display the study number, study description, lead investigator(s), accrual goal, and the date the trial was activated (began enrolling patients). Please read the ECOG-ACRIN Disclaimer in its entirety before accessing this information.
To inquire about a particular trial, send us an email using our contact form. Alternatively, send an email to the study chair; click on their hyperlinked name and a new email window will open. To view educational materials, click on the links provided in the Educational Materials column.
Myeloma Trials Currently Recruiting Participants
STUDY DESCRIPTION ECOG-ACRIN STUDY CHAIR
E1A11 aka ENDURANCE Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Shaji K. Kumar, MD
Adam Cohen, MD, Co-Chair
(Susanna Jacobus, MS)
756 11/13/2013 E1A11 Resources
PrECOG PrE1003 A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function
Note: The Phase I portion of PrE1003 completed accrual on December 18, 2012.
Joseph R. Mikhael, MD
(Judith Manola, MS)
111 07/28/2011 PrE1003 Resources